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Withaferin-A dose-dependently (10 tob40 mg/kg) displayed anxiolytic activity, as measured by an 
increase in open arm exploration time in the elevated plus-maze (EPM), following intraperitoneal (i.p.) 
administration in rats. Acute administration of withaferin-A at 40.0 mg/kg significantly (P<0.05) 
increased open arm exploration time by 176% as compared to vehicle control, which is similar to the 
benzodiazepine diazepam at 1.0 and 3.0 mg/kg (191 and 200%, respectively). However, 24 h following 
sub chronic 5-day administration of diazepam twice daily (bid) at 3.0 mg/kg, diazepam was devoid of 
anxiolytic activity at 1.0 mg/kg, as measured by no difference in open arm exploration time when 
compared with vehicle control, while the 3.0 mg/kg dose still produced a significant (P<0.05) 175% 
increase in open arm exploration time. In contrast, following sub chronic administration of withaferin-A 
(40.0 mg/kg), a significant (P<0.01) enhancement in open arm exploration time was observed at 40.0 
mg/kg (665% as compared to control). Therefore, withaferin-A resulted in anxiolysis which is similar to 
diazepam following acute administration in the EPM. However, following sub chronic administration 
unlike diazepam which showed an attenuation of anxiolytic activity, withaferin-A displayed enhanced 
anxiolytic efficacy and was devoid of tolerance. 
 





Withania somnifera Dunal (WS), known as Ashwagandha 
or Indian ginseng has been commonly used in Indian 
traditional medicines for over 3,000 years. WS has been 
categorized as Rasayana in Ayurveda, which is known to 
augment defense against diseases, arrest aging, revita-
lize the body in debilitated condition, increase the capa-
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Abbreviations: RS, Restrained stress; HPLC, high 
performance liquid chromatography; nNOS, neuronal nitric 
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intraperitonealy; BZD, benzodiazepines; EPM, elevated plus 
maze; WS, Withania somnifera Dunal. 
factors and create a  sense  of  mental  wellbeing  (Bone, 
1996; Bhatnagar et al., 2005). Earlier studies have report-
ed multiple properties of WS, such as antioxidant, 
adaptogenic, aphrodisiac, liver tonic, astringent and, also 
as an anti-inflammatory and anti-ulcer agent (Gupta and 
Rana, 2007). It has also been used to treat stress, 
insomnia, arthritis and age related disorders including 
neurodegeneration (Gupta et al., 2003; Mishra et al., 
2000). The biologically active constituents in WS are 
alkaloids (ashwagandhin, cuscohygrine, anahygrine, 
topine, etc.), steroidal compounds including ergostane 
type teroidallactones, withaferin-A, withanolides A–Y, 
with asomniferin A, withasomnidienone, withasomnierose 
A–C, withanone, etc. Other constituents include saponins 
containing an additional acyl group (sitoindoside VII and 
VIII), and withanolides with a glucose at carbon 27 
(sitoindoside IX and X) (Elsakka et al., 1990; Ganzera et 
al., 2003).  It  has  been  suggested  that  withaferin-A   in  




doses of 40 and 50 mg/kg, causes a  mild anxiolytic-like  
behavior   (Khan    and  Ghosh,  2010).  Benzodiazepines 
(BZDs), such as diazepam, have been shown to produce 
anxiolysis both preclinically (Cook and Davidson, 1973) 
and clinically (Haefely, 1991). Tolerance, a phenomenon 
observed when the effects following an initial 
administration of a drug at a given dose are no longer 
observed or are significantly reduced after repeated 
administration, is a prominent side effect associated with 
BZD administration. BZDs have also shown tolerance to 
their anxiolytic effects in the conflict model (Smith et al., 
1996). Therapeutically, tolerance is an undesirable side 
effect and may also be linked to dependence liability 
(Kolesnikov et al., 1993).The purpose of this study was to 
investigate whether repeated systemic sub chronic 
administration of a withaferin-A would produce tolerance 
to the anxiolytic effects observed following acute 
administration in the EPM. Withaferin-A, which has in 
vivo selectivity for nNOS and is devoid of hypertensive 
activity (Moore et al., 1993a) was compared with the 
benzodiazepine diazepam following acute and sub 
chronic administration in the EPM paradigm. 
 
 
MATERIALS AND METHODS 
 
Male Wistar rats (150 to 200 g) were used in this study. Rats were 
housed at a constant temperature of 20 ± 2°C under a 12-h light : 
12-h dark cycle. The animals (n = 6 per group) had free access to 
food and water throughout the experiments. Animal care was as per 
Indian National Science Academy (INSA) Guidelines for the Care 
and Use of Animals in Scientific Research, and the study had the 
approval of Institutional Animal Ethical Committee (IAEC). 
The following drugs were used: L-Arginine and D-Arginine (Sigma 
Aldrich). All drugs were freshly prepared and given intraperitonealy 
(i.p.) in a volume of 0.1 ml/100 g body weight of rats at different 
time intervals before the testing. 
 
 
Extraction of withaferin-A and drugs 
 
The roots of W. somnifera grown in natural habitat and purchased 
from an authorized dealer were air-dried in shade and finely 
powdered. The chief botanist at Indian Agricultural Research 
Institute (IARI), New Delhi, India, identified the roots and a voucher 
specimen (accession number NISCAIR/RHM/F-
3/2008/Consult/473) has been deposited at the herbarium of IARI. 
The root powder was exhaustively extracted with methanol : water 
(4:1, v/v) under reflux (WS). This extract was partitioned with 
chloroform and water to give WS-chloroform and WS-water, 
respectively. WS-chloroform was subjected to 12 successive 
elutions of water and acetonitrile (ACN) and these elutions were 
labeled from A1 to A12. 
HPLC (Waters, Milford, U.S.A.) of W. somnifera extracts was 
performed using Kromasil C8 column (4.6 mm × 25 cm, 5 µm), and 
the mobile phase consisted of ACN and water (1:1, v/v) at a flow 
rate of 1 ml/min for a run time of 40 min. The HPLC of fractions was 
conducted using Novapak C18 column (3.9 mm × 15 cm, 4 µm) and 
the mobile phase consisted of potassium-dihydrogen 
orthophosphate (0.05 M) and ACN (3:7, v/v) at the flow rate of 
1.5 ml/min for a run time of 40 min. The photodiode array (PDA) 
detector was set to detect at 229 nm and scan spectral data from 
190 to 400 nm. Using the standard withaferin-A (Natural Remedies 





extracts were quantified by external calibration method. 
 
 
Elevated plus maze 
 
The elevated plus maze (Pellow et al., 1985; Pellow and File, 1986) 
was elevated to a height of 50 cm and consisted of two open arms 
50 x 10 cm, and two enclosed arms 50 x 10 x 40 cm, arranged such 
that the two arms of each type were opposite each other. The 
apparatus and procedure have been previously described (Volke et 
al., 1997). During a 5-min observation period, the following 
parameters were measured: number of open arm entries, time 
spent on open arms and number of closed arm entries. 
Subsequently, the percentage of the number of entries into the 
open arms of the total number of entries into all arms and 





Rats were subjected to restrained stress for 1 h and then 
administered diazepam (0.3, 1.0 or 3.0 mg/kg) or vehicle controlled 
(distilled water plus one drop of Tween 80) 30 min prior to testing in 
EPM. On days 2 to 6 (sub chronic drug administration), animals 
were administered diazepam twice daily at 3.0 mg/kg, i.p (08:30 
and 17:30 h). On day 7, animals were administered diazepam after 
RS (0.3, 1.0 or 3.0 mg/kg). Same 7 day protocol was followed with 
administration of withaferin-A (10, 30 or 40 mg/kg) or vehicle. For 






The mean ± S.E.M. open arm exploration time (s) and total arm 
entries for each dose group was compared with the vehicle treated 
group. Dose response effects for acute vs. sub chronic dosing were 
compared by a one-way analysis of variance (ANOVA) followed by 
a Dunnett's test for post hoc comparison. Significance was 





Both diazepam and withaferin-A dose-dependently 
increased open arm exploration time following acute 
administration. Figure 1 shows that diazepam at 1.0 and 
3.0 mg/kg significantly (P<0.05) increased open arm 
exploration time by 191 and 200%, respectively as 
compared to the vehicle (0.0 mg/kg) control (F3.20 = 5.31; 
P<0.01). Furthermore, diazepam at 3.0 mg/kg 
significantly (P<0.05) increased overall motor activity 
(total arm entries) by 84% as compared to vehicle control 
(F3.20 = 4.75; P<0.05). Similarly, acute administration of 
withaferin-A at 40 mg/kg produced significant (P<0.05) 
anxiolytic activity (Figure 2) by increasing open arm 
exploration time by 176% as compared to the vehicle 
control (F3.20 = 4.29; P<0.05); although, there was no 
significant change in overall motor activity following acute 
administration of withaferin-A (F3.20 = 0.83; P>0.05). 
The effects of both diazepam and withaferin-A following 
sub chronic bid administration differed from those of 
acute administration. Following sub chronic drug 
administration,   diazepam      at   3.0  mg/kg,    (Figure 1)  
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Figure 1. The effects of diazepam (0.0, 0.3, 1.0 and 3.0 mg/kg, i.p.) on open arm exploration 
time in seconds (X±S.E.M.; top) and total number of arm entries (X±S.E.M.; bottom) following 
acute and 5 day sub chronic (3.0 mg/kg, bid) diazepam treatment are depicted. Per dose 





significantly (P<0.05) increased open arm exploration 
time by 175% in comparison with the vehicle (0.0 mg/kg) 
control  (F3.20 = 3.41; P<0.05). The  effects on  open arm 
exploration time following acute administration of 3.0 
mg/kg diazepam and following 5 days of 3.0 mg/kg bid 
dosing were not significantly different (F3.20 = 2.28; 
P>0.05). However, following sub chronic drug 
administration, the animals administered 1.0 mg/kg did 
not show significant anxiolytic effects in open arm 
exploration when compared  with  vehicle  control  (F3.20 = 









Treatment with WA i.p (mg/kg) 


























Figure 2. The effects of WA (10.0, 30.0 and 40.0 mg/kg, i.p.) on open arm exploration time 
in s (X±S.E.M.; top) and total number of arm entries (X±S.E.M.; bottom) following acute 
and 5-day sub chronic (40.0 mg/kg, bid) WA are depicted. Per dose group, n = 6. *P<0.05 




2.28; P>0.05). There was a significant (P<0.05) 65% 
decrease in open arm exploration time, when acute 
effects of 1.0 mg/kg were compared with the effects 
following sub chronic administration (F7.40 = 4.10; 
P<0.01). For overall motor activity, the 3.0 mg/kg dose 
was no longer significantly different from vehicle control 
(F3.20 = 1.24; P>0.05). 





withaferin-A (Figure 2) significantly (P<0.05) increased 
open arm exploration time by 409 and 665%, respectively 
as compared to the vehicle control (F3.20 = 4.80; P<0.01). 
In addition, open arm exploration time following sub 
chronic injections was significantly (P<0.05) greater by 
172% than following acute administration of withaferin-A 
at 40.0 mg/kg (F7.40 = 12.13; P<0.01). Following sub 
chronic drug administration, withaferin-A demonstrated a 
significant (P<0.05) increase in overall motor activity at 
10.0 and 40.0 mg/kg by 37 and 63%, respectively as 





Both diazepam and withaferin-A produced a dose 
dependent anxiolytic effect as measured by open arm 
exploration time in the EPM following acute 
administration. However, sub chronic administration of 
diazepam, which acutely produced anxiolytic effects at 
1.0 mg/kg, was devoid of anxiolytic activity at 1 mg/kg, 
suggesting tolerance to its anxiolytic effects. In contrast, 
withaferin-A showed enhanced anxiolytic efficacy 
following sub chronic administration when compared to 
its effects following acute administration. 
In this study, the benzodiazepine diazepam 
demonstrated anxiolytic effects by increasing open arm 
exploration time in the EPM. These findings are in 
agreement with previous studies that have shown 
diazepam to produce consistent anxiolytic effects both 
preclinically (Cook and Davidson, 1973) and clinically 
(Haefely, 1991). This study further demonstrated that the 
withaferin-A produced anxiolytic effects by increasing 
open arm exploration time. These findings are in 
agreement with recent reports that showed that 
withaferin-A have demonstrated anti-anxiety effects 
similar to benzodiazepines in preclinical models (Khan 
and Ghosh, 2010). In addition, the anxiolytic activity of 
withaferin-A was independent of benzodiazepine receptor 
activation (Bhatnagar et al., 2005). Furthermore, in 
rodents, withaferin-As were devoid of benzodiazepine-
like side effects such as motor in-coordination and 
amnesia (Bhatnagar et al., 2005).  
In addition, the benzodiazepine diazepam has been 
shown to produce tolerance to its anxiolytic effects 
following sub chronic dosing in the conflict assay (Smith 
et al., 1996) and in the EPM in this study. Tolerance is an 
undesirable side effect for therapeutic purposes and may 
also be linked to dependence liability (Kolesnikov et al., 
1993). This study shows that withaferin-A was devoid of 
tolerance to its anxiolytic effects. The similar open arm 
times in the vehicle control groups in the acute and sub 
chronic EPM paradigms in this study as well as previous 
EPM studies in rats show that a single prior experience in 
the EPM has no effect on open arm time or total arm 
entries following retesting (Pellow et al., 1985).  
Therefore,  this  findings  are  most  likely  due  to  the 
inherent  pharmacological   properties   of diazepam   and 





Tolerance to benzodiazepines has been associated 
with down regulation of the GABAA-benzodiazepine 
receptor complex (GBR) (Sher et al., 1983). The reason 
for lack of tolerance following sub chronic administration 
of a withaferin-A is presently unknown, but may be 
related to the mechanism of action of withaferin-A, 
namely, enzymatic inhibition rather than a receptor 
mediated interaction. By enzymatically mediating the 
release of NO, and not directly affecting receptor site(s), 
down regulation and resulting tolerance at a receptor site 
may be avoided. 
Another important consideration concerning our results 
of enhanced anxiolytic efficacy following sub chronic 
administration of withaferin-A involves reversible vs. 
irreversible inhibition of NOS by various withaferin-A. 
Based on these findings, it might be expected that 
repeated administration of an irreversible withaferin-A 
would produce an increase in NOS inhibition, an 
increased duration of effect and possible enhanced 
anxiolytic activity following sub chronic administration. 
However, these enhanced effects would not be expected 
with a reversible inhibitor such as withaferin-A. It is 
unclear as to why repeated administration of withaferin-A 
in this study produced enhanced anxiolytic efficacy. 
Enzymatic studies are currently underway to investigate 
the effects of sub chronic administration of withaferin-A 
on NOS activity. 
In conclusion, acute inhibition of nitric oxide synthase 
by withaferin-A resulted in anxiolysis which is similar to 
diazepam. However, following sub chronic administration 
unlike diazepam, withaferin-A displayed enhanced 
anxiolytic efficacy without tolerance. These findings 
suggest that withaferin-As may represent a novel class of 
anti-anxiety agents which may produce continued 
anxiolytic efficacy following repeated administration, 
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